On-X Aortic Heart Valve
Real-world outcomes with Low Dose Anticoagulation
Key Facts
Indication
Real-world outcomes with Low Dose Anticoagulation
Phase
Post-Market Study
Status
Ongoing; Data presented
Company
About Artivion
Artivion (NYSE: AORT) is a specialized medical device innovator with a mission to deliver breakthrough technologies for aortic disease. The company has built a synergistic portfolio through strategic acquisitions like On-X and Ascyrus Medical, achieving significant milestones including recent FDA HDE approval for its flagship AMDS device. Its strategy centers on dominating the high-complexity aortic surgery market with a combination of biological tissues, advanced prosthetics, and novel hybrid stent-graft systems.
View full company profile